Table 4 Availability of nano-pharmaceutical drugs in Palestinian hospitals
No. | Nano-drug | Total | Government | Private | NGOs | P-value |
|---|---|---|---|---|---|---|
N = 56 (%) | N = 29 (%) | N = 17 (%) | N = 10 (%) | |||
1 | Ambisome® | 17 (30.4) | 8 (14.3) | 6 (10.7) | 3 (5.4) | 0.860 |
2 | Rapamune® | 5 (8.9) | 3 (5.4) | 0 (0.0) | 2 (3.6) | 0.197 |
3 | Ritalin La® | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | > 0.999 |
4 | Emend® | 3 (5.4) | 0 (0.0) | 0 (0.0) | 3 (5.4) | 0.001 |
5 | Swiss Relief® | 22 (39.3) | 1 (1.8) | 14 (25.0) | 7 (12.5) | < 0.001 |
6 | Invega® | 1 (1.8) | 0 (0.0) | 1 (1.8) | 0 (0.0) | 0.311 |
7 | Doxil® | 2 (3.6) | 2 (3.6) | 0 (0.0) | 0 (0.0) | 0.381 |
8 | Epaxal® | 4 (7.1) | 1 (1.8) | 1 (1.8) | 2 (3.6) | 0.209 |
9 | Mepact® | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | > 0.999 |
10 | Mircera® | 1 (1.8%) | 1 (1.8) | 0 (0.0) | 0 (0.0) | 0.623 |
11 | Pegasys® | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | > 0.999 |
12 | Somavert® | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | > 0.999 |